- Home
- BRSP vs GYRE Comparison
BRSP vs GYRE Comparison
Compare BRSP & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRSP
- GYRE
- Stock Information
- Founded
- BRSP 2017
- GYRE 2002
- Country
- BRSP United States
- GYRE United States
- Employees
- BRSP N/A
- GYRE N/A
- Industry
- BRSP Real Estate Investment Trusts
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- BRSP Real Estate
- GYRE Health Care
- Exchange
- BRSP Nasdaq
- GYRE Nasdaq
- Market Cap
- BRSP 683.8M
- GYRE 755.7M
- IPO Year
- BRSP 2018
- GYRE N/A
- Fundamental
- Price
- BRSP $5.45
- GYRE $7.76
- Analyst Decision
- BRSP Buy
- GYRE Strong Buy
- Analyst Count
- BRSP 3
- GYRE 2
- Target Price
- BRSP $6.00
- GYRE $17.00
- AVG Volume (30 Days)
- BRSP 592.4K
- GYRE 89.5K
- Earning Date
- BRSP 10-28-2025
- GYRE 11-12-2025
- Dividend Yield
- BRSP 12.01%
- GYRE N/A
- EPS Growth
- BRSP N/A
- GYRE N/A
- EPS
- BRSP N/A
- GYRE 0.02
- Revenue
- BRSP $335,107,000.00
- GYRE $102,189,000.00
- Revenue This Year
- BRSP N/A
- GYRE $15.25
- Revenue Next Year
- BRSP $0.74
- GYRE $33.14
- P/E Ratio
- BRSP N/A
- GYRE $454.73
- Revenue Growth
- BRSP N/A
- GYRE N/A
- 52 Week Low
- BRSP $4.16
- GYRE $6.11
- 52 Week High
- BRSP $6.45
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- BRSP 46.74
- GYRE 47.04
- Support Level
- BRSP $5.28
- GYRE $7.75
- Resistance Level
- BRSP $5.39
- GYRE $8.37
- Average True Range (ATR)
- BRSP 0.11
- GYRE 0.44
- MACD
- BRSP 0.02
- GYRE -0.03
- Stochastic Oscillator
- BRSP 74.60
- GYRE 24.66
About BRSP BrightSpire Capital Inc.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.